Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.
Véniant MM, Lu SC, Atangan L, Komorowski R, Stanislaus S, Cheng Y, Wu B, Falsey JR, Hager T, Thomas VA, Ambhaikar M, Sharpsten L, Zhu Y, Kurra V, Jeswani R, Oberoi RK, Parnes JR, Honarpour N, Neutel J, Strande JL. Véniant MM, et al. Among authors: sharpsten l. Nat Metab. 2024 Feb;6(2):290-303. doi: 10.1038/s42255-023-00966-w. Epub 2024 Feb 5. Nat Metab. 2024. PMID: 38316982 Free PMC article. Clinical Trial.
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Varin C, Honarpour N, Abbasi SA, Malik FI, Kurtz CE; GALACTIC-HF Investigators. Teerlink JR, et al. Among authors: sharpsten l. N Engl J Med. 2021 Jan 14;384(2):105-116. doi: 10.1056/NEJMoa2025797. Epub 2020 Nov 13. N Engl J Med. 2021. PMID: 33185990 Clinical Trial.
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials.
Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria Correa LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Abbasi SA, Varin C, Malik FI, Kurtz CE; GALACTIC-HF Investigators. Teerlink JR, et al. Among authors: sharpsten l. Eur J Heart Fail. 2020 Nov;22(11):2160-2171. doi: 10.1002/ejhf.2015. Epub 2020 Oct 27. Eur J Heart Fail. 2020. PMID: 32985088 Free PMC article. Clinical Trial.
Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
Moretz C, Sharpsten L, Bengtson LG, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R. Moretz C, et al. Among authors: sharpsten l. Int J Chron Obstruct Pulmon Dis. 2019 Aug 1;14:1721-1737. doi: 10.2147/COPD.S204649. eCollection 2019. Int J Chron Obstruct Pulmon Dis. 2019. PMID: 31534326 Free PMC article.
Impact of pill burden on adherence to hepatitis C medication.
An J, Lee JS, Sharpsten L, Wilson AK, Cao F, Tran JN. An J, et al. Among authors: sharpsten l. Curr Med Res Opin. 2019 Nov;35(11):1937-1944. doi: 10.1080/03007995.2019.1643160. Epub 2019 Sep 25. Curr Med Res Opin. 2019. PMID: 31298592
The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models.
Buikema AR, Brekke L, Anderson A, Koep E, Van Voorhis D, Sharpsten L, Hahn B, Ray R, Stanford RH. Buikema AR, et al. Among authors: sharpsten l. Multidiscip Respir Med. 2018 Oct 11;13:38. doi: 10.1186/s40248-018-0151-6. eCollection 2018. Multidiscip Respir Med. 2018. PMID: 30338068 Free PMC article.
Rate and Pattern of Rim Area Loss in Healthy and Progressing Glaucoma Eyes.
Hammel N, Belghith A, Bowd C, Medeiros FA, Sharpsten L, Mendoza N, Tatham AJ, Khachatryan N, Liebmann JM, Girkin CA, Weinreb RN, Zangwill LM. Hammel N, et al. Among authors: sharpsten l. Ophthalmology. 2016 Apr;123(4):760-70. doi: 10.1016/j.ophtha.2015.11.018. Epub 2015 Dec 30. Ophthalmology. 2016. PMID: 26746597 Free PMC article.
18 results